Shopping Cart

Your shopping cart is currently empty

dTAGV-1 TFA

Name: dTAGV-1 TFA
Brand: TargetMol
SKU: T40251
Price: 147 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. T40251 Copy Product Info

Purity: 99.73%

🥰Excellent

dTAGV-1 TFA is a highly efficient, highly selective VHL-dependent PROTAC-mediated protein degrader that specifically targets and degrades mutant FKBP12 fusion proteins. dTAGV-1 TFA efficiently induces the degradation of FKBP12 fusion proteins at both the cellular and in vivo levels.

dTAGV-1 TFA

Copy Product Info

🥰Excellent

Catalog No. T40251

Cas No. 2624313-15-9

Pack Size	Price	USA Stock	Global Stock
1 mg	$147	-	In Stock
5 mg	$372	-	In Stock
10 mg	$633	-	In Stock
25 mg	$863	-	In Stock
50 mg	$1,160	-	In Stock
100 mg	$1,570	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.73%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	dTAGV-1 TFA is a highly efficient, highly selective VHL-dependent PROTAC-mediated protein degrader that specifically targets and degrades mutant FKBP12 fusion proteins. dTAGV-1 TFA efficiently induces the degradation of FKBP12 fusion proteins at both the cellular and in vivo levels.
In vitro	Methods: PATU-8902 FKBP12F³⁶V-KRASG¹²V cells were treated with dTAGV-1 TFA (500 nM) for 4 hours, and KRASG¹²V expression levels were detected by Western blot. Results: dTAGV-1 TFA induced KRASG¹²V degradation (4 hours). [1] Method: 293T WT and 293T VHL⁻/⁻ cells (both expressing FKBP12F³⁶V-KRASG¹²V) were treated with dTAGV-1 TFA (500 nM) for 4 hours, and KRASG¹²V expression levels were detected by Western blot. Results: dTAGV-1 TFA failed to degrade KRASG¹²V in VHL⁻/⁻ cells, demonstrating that its action is VHL-dependent.[1]
In vivo	Methods: To investigate the in vivo pharmacokinetics (PK) of dTAGV-1 TFA, female NSG mice (8 weeks old) were selected. After tail vein inoculation with MV4;11 luc-FKBP12F³⁶V cells, the mice received daily intraperitoneal injections of dTAGV-1 TFA (35 mg/kg) for 3 consecutive days, followed by in vivo imaging 4 hours after the final dose. Results: Four hours after the first administration, the bioluminescence signal in the dTAGV-1 group decreased significantly, and the degradation effect persisted 28 hours after the final administration.[1]

Chemical Properties

Molecular Weight	1361.58
Formula	C₇₀H₉₁F₃N₆O₁₆S
Cas No.	2624313-15-9
Smiles	C(C(O)=O)(F)(F)F.[C@@H](OC(=O)[C@H]1N(C([C@@H](CC)C2=CC(OC)=C(OC)C(OC)=C2)=O)CCCC1)(CCC3=CC(OC)=C(OC)C=C3)C4=C(OCC(NCCCCCCC(N[C@H](C(=O)N5[C@H](C(N[C@@H](C)C6=CC=C(C=C6)C=7SC=NC7C)=O)C[C@@H](O)C5)[C@](C)(C)C)=O)=O)C=CC=C4
Relative Density.	no data available

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (58.76 mM)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	0.7344 mL	3.6722 mL	7.3444 mL	36.7220 mL
5 mM	0.1469 mL	0.7344 mL	1.4689 mL	7.3444 mL
10 mM	0.0734 mL	0.3672 mL	0.7344 mL	3.6722 mL
20 mM	0.0367 mL	0.1836 mL	0.3672 mL	1.8361 mL
50 mM	0.0147 mL	0.0734 mL	0.1469 mL	0.7344 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Citations

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc